SCHEDULE 13G

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

	ImmunoGen, Inc.
	(Name of Issuer)
	Common Stock, par value \$0.01 per share
	(Title of Class of Securities)
	45253H101
	(CUSIP Number)
	December 31, 2016
	(Date of Event which Requires Filing of this Statement)
Check the appropriate box to des	signate the rule pursuant to which this Schedule is filed:
☑ Rule 13d-1(b)	
☐ Rule 13d-1(c)	
☐ Rule 13d-1(d)	
	ge shall be filled out for a reporting person's initial filing on this form with respect to the subject class of ment containing information which would alter disclosures provided in a prior cover page.
	re remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the t") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions
	Page 1 of 10 Pages

1	NAMES OF REPORTING PERSONS			
	Baker Bros. Advisors LP			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [(b)]			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
		5	SOLE VOTING POWER	
	NUMBER OF		3,015,353	
	SHARES	6	SHARED VOTING POWER	
	BENEFICIALLY			
	OWNED BY EACH	_	-0- SOLE DISPOSITIVE POWER	
EACH REPORTING 7 SOLE DIS		7	SOLE DISPOSITIVE FOWER	
	PERSON		3,015,353	
	WITH	8	SHARED DISPOSITIVE POWER	
			-0-	
9	AGGREGATE AMOUNT	BEN	EFICIALLY OWNED BY EACH REPORTING PERSON	
9	0.045.050			
4.0	3,015,353	CCD	EGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	(See Instructions)	GGK	EGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(
11	PERCENT OF CLASS RE	EPRE	SENTED BY AMOUNT IN ROW 9	
	3.5% (1)			
10	TYPE OF REPORTING F	PERS	ON (See Instructions)	
12			(
	IA, PN			

(1) This percentage is based upon 87,301,341 shares of Common Stock outstanding of ImmunoGen Inc. (the "Issuer") as of October 27, 2016 as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2016.

Page 2 of 10 Pages

1	NAMES OF REPORTING PERSONS			
	Baker Bros. Advisors (GP) LLC			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b)			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
		5	SOLE VOTING POWER	
	NUMBER OF		3,015,353	
	SHARES		SHARED VOTING POWER	
	BENEFICIALLY OWNED BY -0-			
	EACH		SOLE DISPOSITIVE POWER	
	REPORTING PERSON		3,015,353	
	WITH	8	SHARED DISPOSITIVE POWER	
			-0-	
9	AGGREGATE AMOUNT	BEN	EFICIALLY OWNED BY EACH REPORTING PERSON	
	3,015,353			
10	CHECK BOX IF THE AC	GGR	EGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(See Instructions)			
11	PERCENT OF CLASS RE	EPRE	SENTED BY AMOUNT IN ROW 9	
	3.5% (1)			
12	TYPE OF REPORTING F	PERS	ON (See Instructions)	
	HC, OO			
	110,00			

(1) This percentage is based upon 87,301,341 shares of Common Stock outstanding of the Issuer as of October 27, 2016 as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2016.

Page 3 of 10 Pages

	NAMES OF PEROPENIS	DEL	ACONG.	
1	NAMES OF REPORTING PERSONS			
	Felix J. Baker			
	Felix J. Dakei			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a)			
_				(b) 🗆
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
4	1 CITIZENSHIP OR PLACE OF ORGANIZATION			
	United States			
		5	SOLE VOTING POWER	
		•		
	NUMBER OF		3,015,353	
SHARES BENEFICIALLY 6 SHARED VOTING POWER				
	OWNED BY		-0-	
		7	SOLE DISPOSITIVE POWER	
REPORTING		/		
PERSON			3,015,353	
	WITH	8	SHARED DISPOSITIVE POWER	
			-0-	
_	AGGREGATE AMOUNT	BEN	EFICIALLY OWNED BY EACH REPORTING PERSON	
9				
	3,015,353			
10		GGR	EGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
-0	(See Instructions)			
44	DEDCENT OF CLASS DE	7 DD E	SENTED BY AMOUNT IN ROW 9	
11	FERCENT OF CLASS RI	of IXL	SENTED DI AMOUNI IN ROW 9	
	3.5% (1)			
12	TYPE OF REPORTING P	PERS	ON (See Instructions)	
1-				
	IN, HC			
l				

(1) This percentage is based upon 87,301,341 shares of Common Stock outstanding of the Issuer as of October 27, 2016 as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2016.

Page 4 of 10 Pages

1	NAMES OF REPORTING PERSONS			
	Julian C. Baker			
2				
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States			
		5	SOLE VOTING POWER	
	NUMBER OF		3,015,353	
SHARES		6	SHARED VOTING POWER	
	BENEFICIALLY OWNED BY -0-			
	EACH		SOLE DISPOSITIVE POWER	
	REPORTING PERSON		3,015,353	
	WITH	8	SHARED DISPOSITIVE POWER	
			-0-	
9	AGGREGATE AMOUNT	BEN	EFICIALLY OWNED BY EACH REPORTING PERSON	
	3,015,353			
10	CHECK BOX IF THE AC	GGR	EGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(See Instructions)			
11	PERCENT OF CLASS RE	PRE	SENTED BY AMOUNT IN ROW 9	
	3.5% (1)			
12	TYPE OF REPORTING P	ERS	ON (See Instructions)	
	IN, HC			
	111, 110			

(1) This percentage is based upon 87,301,341 shares of Common Stock outstanding of the Issuer as of October 27, 2016 as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2016.

Page 5 of 10 Pages

Amendment No. 1 to Schedule 13G

This Amendment No. 1 to Schedule 13G amends and supplements the previously filed Schedules 13G filed by Baker Bros. Advisors LP (the "Adviser"). Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

Item 1(a) Name of Issuer:

ImmunoGen, Inc. (the "Issuer")

Item 1(b) Address of Issuer's Principal Executive Offices:

830 Winter Street

Waltham, MA 02451

Item 2(a) Name of Person Filing:

This Schedule 13G is being filed jointly by the Adviser, the Adviser GP, Felix J. Baker and Julian C. Baker (collectively, the "Reporting Persons").

Item 2(b) Address of Principal Business Office or, if None, Residence:

The business address of each of the Reporting Persons is:

c/o Baker Bros. Advisors LP

667 Madison Avenue, 21st Floor

New York, NY 10065

(212) 339-5690

Item 2(c) Citizenship:

The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

Item 2(d) Title of Class of Securities

Common Stock, \$0.01 par value per share ("Common Stock")

Item 2(e) CUSIP Number

45253H101

Page 6 of 10 Pages

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:				
	(a) \square Broker or dealer registered under Section 15 of the Exchange Act.				
	(b) \square Bank as defined in section 3(a)(6) of the Exchange Act.				
	(c) \square Insurance company as defined in section 3(a)(19) of the Exchange Act.				
	(d) \square Investment company registered under section 8 of the Investment Company Act of 1940.				
	(e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).				
	(f) \square An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).				
	(g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).				
	(h) \square A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.				
	(i) \square A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.				
	(j) \square Group, in accordance with Rule 13d-1(b)(1)(ii)(J).				
Item 4.	Ownership.				
held by forth be	through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein reference. Certain securities of the Issuer are directly each of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds"). The information set low is based upon 87,301,341 shares of Common Stock outstanding as of October 27, 2016 as reported in the Issuer's Form 10-Q filed with the SEC ember 3, 2016. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.				
Page 7 of 10 Pages					

	Number of Shares	
	of Common Stock we own or have	Percent of
Nome	the right to acquire	Class
Name	within 60 days	Outstanding
667, L.P.	228,484	0.3%
Baker Brothers Life Sciences, L.P.	2,786,869	3.2%
Total	3 015 353	3.5%

Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the sole power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities held by each of the Funds, and this Amendment No. 1 shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

The information in Item 4 is incorporated herein by reference.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

The information in Item 4 is incorporated herein by reference.

Item 8. Identification and Classification of Members of the Group.

N/A

Page 8 of 10 Pages

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 9 of 10 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2017

BAKER BROS. ADVISORS LP

By: Baker Bros. Advisors (GP) LLC, its general partner

By: /s/ Scott L. Lessing

Name: Scott L. Lessing Title: President

BAKER BROS. ADVISORS (GP) LLC

By: /s/ Scott L. Lessing

Name: Scott L. Lessing
Title: President

/s/ Julian C. Baker

Julian C. Baker

/s/ Felix J. Baker

Felix J. Baker

Page 10 of 10 Pages